Hasselgren P O, Adlerberth A, Angerås U, Stenström G
J Clin Endocrinol Metab. 1984 Nov;59(5):835-9. doi: 10.1210/jcem-59-5-835.
Protein metabolism in skeletal muscle tissue was studied in three groups of patients undergoing thyroid surgery: group I (n = 8), hyperthyroid patients preoperatively treated with an antithyroid drug and T4; group II (n = 8), hyperthyroid patients preoperatively treated with the beta 1-selective adrenoreceptor blocking agent metoprolol; group III (n = 5), euthyroid patients operated on for nodular goiter or adenoma. The study was prospective and hyperthyroid patients were randomly allocated to one of the two preoperative regimens. During operation a biopsy was taken from the sternohyoid muscle and rates of protein synthesis and degradation were measured in incubated muscle tissue. Clinical improvement was equal in the two groups of hyperthyroid patients during preoperative treatment but serum T3 concentrations remained elevated in patients treated with metoprolol. Thus, these patients were biochemically hyperthyroid at the time of operation. The rate of protein degradation was significantly higher in hyperthyroid patients treated with metoprolol than in patients of groups I and III. A significant positive correlation was found between serum T3 and rate of protein degradation in skeletal muscle. Protein synthesis rates were similar in the three groups of patients. This study demonstrated for the first time increased proteolysis in skeletal muscle tissue from patients with high serum T3 concentrations. The results indicate that changes of skeletal muscle protein metabolism in hyperthyroid patients are not normalized by beta 1-blockade despite the fact that this treatment effectively controlled symptoms and signs of hyperthyroidism.
第一组(n = 8),术前用抗甲状腺药物和T4治疗的甲状腺功能亢进患者;第二组(n = 8),术前用β1选择性肾上腺素能受体阻滞剂美托洛尔治疗的甲状腺功能亢进患者;第三组(n = 5),因结节性甲状腺肿或腺瘤接受手术的甲状腺功能正常患者。该研究为前瞻性研究,甲状腺功能亢进患者被随机分配到两种术前治疗方案中的一种。手术期间,从胸骨舌骨肌取活检组织,并在孵育的肌肉组织中测量蛋白质合成和降解速率。两组甲状腺功能亢进患者在术前治疗期间临床改善情况相同,但美托洛尔治疗的患者血清T3浓度仍升高。因此,这些患者在手术时生化指标仍显示甲状腺功能亢进。用美托洛尔治疗的甲状腺功能亢进患者的蛋白质降解速率明显高于第一组和第三组患者。血清T3与骨骼肌蛋白质降解速率之间存在显著正相关。三组患者的蛋白质合成速率相似。这项研究首次证明血清T3浓度高的患者骨骼肌组织中的蛋白水解增加。结果表明,尽管β1阻滞剂有效控制了甲状腺功能亢进的症状和体征,但甲状腺功能亢进患者骨骼肌蛋白质代谢的变化并未因β1阻滞剂而恢复正常。